

Jian Xu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4419850/publications.pdf>

Version: 2024-02-01

20
papers

525
citations

933447

10
h-index

794594

19
g-index

20
all docs

20
docs citations

20
times ranked

598
citing authors

#	ARTICLE	IF	CITATIONS
1	Antibody- α -Pattern Recognition Receptor Agonist Conjugates: A Promising Therapeutic Strategy for Cancer. <i>Advanced Biology</i> , 2022, , 2101065.	2.5	4
2	Loss of ID3 in pancreatic cancer cells increases DNA damage without impairing MDC1 recruitment to the nuclear foci. <i>Cancer Communications</i> , 2022, 42, 269-272.	9.2	3
3	Nanocarrier-delivered small interfering <scp>RNA</scp> for chemoresistant ovarian cancer therapy. <i>Wiley Interdisciplinary Reviews RNA</i> , 2021, 12, e1648.	6.4	8
4	Advances and challenges in the treatment of esophageal cancer. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 3379-3392.	12.0	101
5	Novel Humanized Mesothelin-Expressing Genetically Engineered Mouse Models Underscore Challenges in Delivery of Complex Therapeutics to Pancreatic Cancers. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2082-2092.	4.1	1
6	Engineered Bifunctional Proteins for Targeted Cancer Therapy: Prospects and Challenges. <i>Advanced Materials</i> , 2021, 33, e2103114.	21.0	6
7	Enhancing the Therapeutic Efficacy of Gefitinib in Human Non-Small-Cell Lung Cancer through Drug Combination. <i>Molecular Pharmaceutics</i> , 2021, 18, 1397-1407.	4.6	5
8	Drug resistance to targeted therapeutic strategies in non-small cell lung cancer. , 2020, 206, 107438.		117
9	Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors. <i>Biomolecules</i> , 2020, 10, 973.	4.0	16
10	Albumin-Mediated Delivery of Bioactive Peptides for Pancreatic Cancer Therapy. <i>Advanced Therapeutics</i> , 2020, 3, 2000003.	3.2	3
11	CDK1/p110 plays a critical role in the tumorigenicity of esophageal squamous cell carcinoma cells and is a potential drug target. <i>Cell Cycle</i> , 2019, 18, 452-466.	2.6	10
12	Nanoparticle systems for cancer vaccine. <i>Nanomedicine</i> , 2019, 14, 627-648.	3.3	85
13	Intensive fibrosarcoma-binding capability of the reconstituted analog and its antitumor activity. <i>Drug Delivery</i> , 2018, 25, 102-111.	5.7	5
14	Enediynes-activated, EGFR-targeted human β -defensin 1 has therapeutic efficacy against non-small cell lung carcinoma. <i>Laboratory Investigation</i> , 2018, 98, 1538-1548.	3.7	10
15	EGFR-targeting, β -defensin-tailored fusion protein exhibits high therapeutic efficacy against EGFR-expressed human carcinoma via mitochondria-mediated apoptosis. <i>Acta Pharmacologica Sinica</i> , 2018, 39, 1777-1786.	6.1	20
16	Targeted drugs for systemic therapy of lung cancer with brain metastases. <i>Oncotarget</i> , 2018, 9, 5459-5472.	1.8	47
17	Substituted 4-oxo-crotonic acid derivatives as a new class of protein kinase B (PknB) inhibitors: synthesis and SAR study. <i>RSC Advances</i> , 2017, 7, 4763-4775.	3.6	12
18	Recombinant EGFR/MMP-2 bi-targeted fusion protein markedly binding to non-small-cell lung carcinoma and exerting potent therapeutic efficacy. <i>Pharmacological Research</i> , 2017, 126, 66-76.	7.1	28

#	ARTICLE	IF	CITATIONS
19	A novel protein kinase inhibitor IMB-YH-8 with anti-tuberculosis activity. <i>Scientific Reports</i> , 2017, 7, 5093.	3.3	21
20	An engineered TIMP2-based and enediyne-integrated fusion protein for targeting MMP-14 shows potent antitumor efficacy. <i>Oncotarget</i> , 2015, 6, 26322-26334.	1.8	23